Company / EPS (Basic)
Gilead Sciences EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
$4.54
FY2025
5-year range
$0.10 / $4.96
FY2021-FY2025
Trend
+24.0%
vs FY2024
Sector context
#12 of 208
Health Care
What the data says
Among 208 Health Care companies, Gilead Sciences is in the top 6% for eps (basic). EPS (Basic) has fluctuated over the past 10 years, ranging from $0.10 in FY2022 to $12.37 in FY2017.
Based on SEC 10-K filings.
4.54 in FY2025 with a 5-year CAGR of +1.6%. Top quartile in the Health Care sector.
Declined from $4.96 to $4.54 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- +256.7%
- 5-Year CAGR
- +1.6%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 208This company $4.54 Sector average -$0.87
▼
+621.5% above sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 24.0% year-over-year.
- Ranks #12 out of 208 companies in the Health Care sector.
- Peak eps (basic) was recorded in FY2017.
- Lowest eps (basic) in the period was in FY2022.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.54 | +24.0% |
| FY2024 | $3.66 | -26.2% |
| FY2023 | $4.96 | +4860.0% |
| FY2022 | $0.10 | -97.6% |
| FY2021 | $4.24 | +1.0% |
| FY2020 | $4.20 | +18.6% |
| FY2019 | $3.54 | -64.9% |
| FY2018 | $10.08 | -18.5% |
| FY2017 | $12.37 | +55.6% |
| FY2016 | $7.95 | +295.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026